THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer ...
The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...
For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.
Lexicon Pharmaceuticals is shifting focus to its late-stage pipeline following the FDA's rejection of Zynquista for type 1 ...
Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre, Phase IIb PROGRESS trial of the new ...
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price ...
Stocktwits on MSN1mon
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment SoursShares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate ...
Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton ...
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback